Skip to main content

Table 2 Descriptive statistics of the proof-of-concept cohort and the clinical cohort

From: Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease

 

Proof of concept cohort

  

Clinical groups

Control

AD-dem

p . value

Count, N (50 total)

25

25

-

Sex F/M

10/15

16/9

0.157

Age (years), mean (SD)

63 (9)

68 (8)

0.047

CSF Ab42 (pg/mL), median (IQR)

1213 (1062—1585)

491 (433—623)

< 0.001

CSF Tau (pg/mL), median (IQR)

208 (166—234)

449 (340—527)

< 0.001

CSF pTau181 (pg/mL), median (IQR)

17.5 (13.8 – 19.6)

41.9 (33.5 – 53.4)

< 0.001

CSF N-terminus β-syn (pg/mL), median (IQR)

174 (138–217)

317 (262–389)

< 0.001

CSF mid-region β-syn (pg/mL), median (IQR)

36 (28–47)

73 (56–86)

< 0.001

CSF C-terminus β-syn (pg/mL), median (IQR)

79 (56–106)

177 (148–243)

< 0.001

Clinical cohort

Clinical groups

Control

SCD-AD

MCI-AD

AD-dem

p. value

Count, N (160 total)

41

39

40

40

-

Sex F/M

23/18

17/22

20/20

20/20

0.741

Age (years), mean (SD)

64 (3)

66 (3)

66 (3)

65 (3)

0.021

MMSE-score, mean (SD)

27.9 (1.7)

28.1 (1.4)

26.6 (2.2)

19.9 (5.2)

< 0.001

TMT A, median (IQR)

37.0 (33.5 – 41.0)

38.0 (29.5 – 44.0)

42.5 (30.8 – 49.0)

55.5 (37.5 – 87.8)

0.001

TMT B, median (IQR)

90.5 (69.5 – 123.0)

90.0 (76.5 – 132.0)

107.0 (88.0 – 144.0)

208.0 (99.0 – 252.0)

< 0.001

TMT B / TMT A, median (IQR)

2.5 (2.1 – 3.0)

2.6 (2.2 – 3.2)

2.6 (2.2 – 3.4)

4.8 (2.9 – 6.1)

< 0.001

TMT B – TMT B, median (IQR)

57.0 (39.5 78.8)

53.0 (42.0 – 79.0)

72.0 (43.5 – 102.0)

167.0 (63.0 – 220)

< 0.001

APOE e4 carriers, %

27%

69%

77.5%

65%

< 0.001

CSF Aβ42 (pg/mL), median (IQR)

1679 (1256–1700)

815 (545–926)

786 (575–916)

581 (472–717)

< 0.001

CSF Tau (pg/mL), median (IQR)

165 (134–235)

248 (186–313)

287 (224–361)

356 (280—539)

< 0.001

CSF pTau181 (pg/mL), median (IQR)

15.7 (11.0–20.1)

24.7 (18.6—33.9)

29.9 (22.0 – 39.4)

39.3 (26.5 – 53.8)

< 0.001

CSF N-terminus β-syn (pg/mL), median (IQR)

162 (109—223)

249 (179—356)

254 (170—330)

268 (158—456)

< 0.001

CSF mid-region β-syn (pg/mL), median (IQR)

36 (27—49)

52 (44—56)

58 (47—86)

62 (46—81)

< 0.001

CSF C-terminus β-syn (pg/mL), median (IQR)

83 (53—129)

152 (79—207)

153 (110—225)

152 (99—233)

< 0.001

  1. The data are presented as the mean, standard deviation (SD), median, interquartile range (IQR), and percentage (%). AD status was determined according to the CSF levels of phosphorylated tau181 (pTau181)/Aβ42 ratio. The pTau181: tau phosphorylated at threonine 181, Aβ42 amyloid beta1-42, β-syn beta-synuclein, SCD subjective cognitive decline, MCI mild cognitive impairment, AD Alzheimer’s disease, MMSE Mini-Mental State Examination, TMT trail making test A and B, TMT B / TMT A: ratio of trail making test B and A, TMT B – TMT B: trail making test A score subtracted from B. CSF biomarker levels were measured using either the Innotest or Elecsys platforms, with Innotest values converted to their Elecsys equivalents using the equations described earlier [31], resulting in a single CSF variable per analyte for consistency. We applied the Kruskal–Wallis’s test to determine the differences between the groups and the results are reported as p values. The results were rounded
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193